1. Ginkgo Bioworks licenses ProteoNic's 2G UNic technology for a $22.2 million project. 2. The project aims to enhance monoclonal antibody production for filovirus infections. 3. Increased efficiency and lower costs are key goals of the collaboration. 4. This partnership aligns with public health priorities and global biomanufacturing resilience. 5. ProteoNic's technology promises improved gene expression in mammalian systems.
FAQ
Why Bullish?
The licensing deal can enhance Ginkgo's revenue potential and market position. Given previous instances of strategic partnerships driving stock prices, this collaboration may improve Ginkgo’s valuation.
How important is it?
The collaboration is likely to enhance Ginkgo's operations, thus impacting its stock positively in the long run.
Why Long Term?
The benefits from increased efficiency in biomanufacturing will accumulate over time, especially as demand for mAbs rises.
Ginkgo Bioworks Licenses ProteoNic's 2G UNic® Technology for Monoclonal Antibody Manufacturing
Leiden, The Netherlands – December 11, 2025 – ProteoNic BV has announced that its proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks (NYSE: DNA) as part of a significant project backed by the Biomedical Advanced Research and Development Authority (BARDA). This collaboration falls under BARDA’s Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) and is designed to develop innovative solutions for reducing the costs associated with domestic biomanufacturing of monoclonal antibodies (mAbs) targeting filovirus infections such as Ebola (EBOV) and Sudan Virus (SUDV).
Details of the Project and Financial Backing
The project is valued at up to $22.2 million and includes a collaboration with reputable organizations such as Advanced BioScience Laboratories (ABL), Isolere Bio by Donaldson, and NeuImmune. Together, these partners will work on developing and integrating advanced technologies throughout the entire mAb production process—from cell line development to purification—with the goal of offering a more rapid, scalable, and cost-effective approach to producing critical medical countermeasures.
Innovative Technology Integration
ProteoNic’s role in the project focuses on its 2G UNic vector and transposon technologies, which are designed to maximize expression and productivity in mammalian systems. By incorporating these innovations, ProteoNic intends to improve manufacturing efficiency and yield, which will significantly minimize both time and costs traditionally associated with large-scale bioproduction.
Leadership Insights
Frank Pieper, CEO of ProteoNic, expressed pride in the partnership, stating, “We are proud that Ginkgo has chosen to license and apply our 2G UNic in this important initiative. Our 2G UNic technology has consistently demonstrated substantial improvements in protein expression and manufacturing productivity. Contributing this capability to a project of such public health importance aligns perfectly with our mission to enable more efficient, accessible biologics production globally.”
Implications for Biomanufacturing and Public Health
This collaboration highlights ProteoNic’s ongoing commitment to advancing next-generation biologics manufacturing. It emphasizes applications in both therapeutic protein production and cell and gene therapies. By enhancing productivity in existing manufacturing infrastructures, ProteoNic’s technology contributes to a sustainable future in biomanufacturing resilience, particularly in response to global health challenges.
Funding and Oversight
The project has received funding through the BioMaP-Consortium, which is managed by Advanced Technology International (ATI) and overseen by BARDA. This initiative is funded in whole or part with federal resources from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); BARDA, under Other Transaction (OT) number #75A50123D00003.
About ProteoNic
ProteoNic is a privately held entity dedicated to providing premium vector and transposon technology for biologics manufacturing. With its innovative 2G UNic technology, ProteoNic offers leading solutions to improve gene expression in mammalian systems, serving biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) globally for therapeutic protein and gene therapy applications.